Risk factors associated with plasma omega-3 fatty acid levels in patients with suspected coronary artery disease

Rahul Chaudhary, Katayoon Saadin, Kevin P. Bliden, William Harris, Bao Dinh, Tushar Sharma, Udaya S. Tantry, Paul A. Gurbel

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Introduction We sought to determine the associations between plasma eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) levels and various cardiovascular risk factors and with the use of fish oil supplements (FOS). Patients and methods Patients with suspected coronary artery disease (CAD) undergoing cardiac catheterization (n=433) were studied. Serum fatty acid (FA) composition, the concentrations of lipids and biomarkers of oxidative stress, and dietary/lifestyle factors were measured. Results FOS use was associated with a higher plasma EPA+DHA levels (3.7±1.5 vs. 2.6±1.1%, p<0.0001). However, there was no relationship between FOS dose (mg/day) and EPA+DHA levels in 76 patients reporting FOS use (r=−0.21, p=0.07). Lower levels were inversely associated with risk factor profiles including lower ApoB100/ApoA1 ratios (p<0.001). Discussion and conclusions Higher EPA+DHA levels characterized patients with lower CAD risk. The lack of relations between FOS dose and plasma EPA+DHA levels likely reflects uncaptured variability in EPA+DHA content of supplements.

Original languageEnglish (US)
Pages (from-to)40-45
Number of pages6
JournalProstaglandins Leukotrienes and Essential Fatty Acids
Volume113
DOIs
StatePublished - Oct 1 2016
Externally publishedYes

Fingerprint

Eicosapentaenoic Acid
Docosahexaenoic Acids
Omega-3 Fatty Acids
Fish Oils
Coronary Artery Disease
Plasmas
Oxidative stress
Biomarkers
Cardiac Catheterization
Life Style
Oxidative Stress
Fatty Acids
Lipids
Serum
Chemical analysis

Keywords

  • Cardiovascular risk
  • Coronary artery disease
  • Docosahexaenoic acid
  • Eicosapentaenoic acid
  • Fish oil supplements
  • Omega-3 fatty acids

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Cell Biology

Cite this

Risk factors associated with plasma omega-3 fatty acid levels in patients with suspected coronary artery disease. / Chaudhary, Rahul; Saadin, Katayoon; Bliden, Kevin P.; Harris, William; Dinh, Bao; Sharma, Tushar; Tantry, Udaya S.; Gurbel, Paul A.

In: Prostaglandins Leukotrienes and Essential Fatty Acids, Vol. 113, 01.10.2016, p. 40-45.

Research output: Contribution to journalArticle

Chaudhary, Rahul ; Saadin, Katayoon ; Bliden, Kevin P. ; Harris, William ; Dinh, Bao ; Sharma, Tushar ; Tantry, Udaya S. ; Gurbel, Paul A. / Risk factors associated with plasma omega-3 fatty acid levels in patients with suspected coronary artery disease. In: Prostaglandins Leukotrienes and Essential Fatty Acids. 2016 ; Vol. 113. pp. 40-45.
@article{da1f3483dceb42eeb82ccada4fe11e93,
title = "Risk factors associated with plasma omega-3 fatty acid levels in patients with suspected coronary artery disease",
abstract = "Introduction We sought to determine the associations between plasma eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) levels and various cardiovascular risk factors and with the use of fish oil supplements (FOS). Patients and methods Patients with suspected coronary artery disease (CAD) undergoing cardiac catheterization (n=433) were studied. Serum fatty acid (FA) composition, the concentrations of lipids and biomarkers of oxidative stress, and dietary/lifestyle factors were measured. Results FOS use was associated with a higher plasma EPA+DHA levels (3.7±1.5 vs. 2.6±1.1{\%}, p<0.0001). However, there was no relationship between FOS dose (mg/day) and EPA+DHA levels in 76 patients reporting FOS use (r=−0.21, p=0.07). Lower levels were inversely associated with risk factor profiles including lower ApoB100/ApoA1 ratios (p<0.001). Discussion and conclusions Higher EPA+DHA levels characterized patients with lower CAD risk. The lack of relations between FOS dose and plasma EPA+DHA levels likely reflects uncaptured variability in EPA+DHA content of supplements.",
keywords = "Cardiovascular risk, Coronary artery disease, Docosahexaenoic acid, Eicosapentaenoic acid, Fish oil supplements, Omega-3 fatty acids",
author = "Rahul Chaudhary and Katayoon Saadin and Bliden, {Kevin P.} and William Harris and Bao Dinh and Tushar Sharma and Tantry, {Udaya S.} and Gurbel, {Paul A.}",
year = "2016",
month = "10",
day = "1",
doi = "10.1016/j.plefa.2016.08.009",
language = "English (US)",
volume = "113",
pages = "40--45",
journal = "Prostaglandins Leukotrienes and Essential Fatty Acids",
issn = "0952-3278",
publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - Risk factors associated with plasma omega-3 fatty acid levels in patients with suspected coronary artery disease

AU - Chaudhary, Rahul

AU - Saadin, Katayoon

AU - Bliden, Kevin P.

AU - Harris, William

AU - Dinh, Bao

AU - Sharma, Tushar

AU - Tantry, Udaya S.

AU - Gurbel, Paul A.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Introduction We sought to determine the associations between plasma eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) levels and various cardiovascular risk factors and with the use of fish oil supplements (FOS). Patients and methods Patients with suspected coronary artery disease (CAD) undergoing cardiac catheterization (n=433) were studied. Serum fatty acid (FA) composition, the concentrations of lipids and biomarkers of oxidative stress, and dietary/lifestyle factors were measured. Results FOS use was associated with a higher plasma EPA+DHA levels (3.7±1.5 vs. 2.6±1.1%, p<0.0001). However, there was no relationship between FOS dose (mg/day) and EPA+DHA levels in 76 patients reporting FOS use (r=−0.21, p=0.07). Lower levels were inversely associated with risk factor profiles including lower ApoB100/ApoA1 ratios (p<0.001). Discussion and conclusions Higher EPA+DHA levels characterized patients with lower CAD risk. The lack of relations between FOS dose and plasma EPA+DHA levels likely reflects uncaptured variability in EPA+DHA content of supplements.

AB - Introduction We sought to determine the associations between plasma eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) levels and various cardiovascular risk factors and with the use of fish oil supplements (FOS). Patients and methods Patients with suspected coronary artery disease (CAD) undergoing cardiac catheterization (n=433) were studied. Serum fatty acid (FA) composition, the concentrations of lipids and biomarkers of oxidative stress, and dietary/lifestyle factors were measured. Results FOS use was associated with a higher plasma EPA+DHA levels (3.7±1.5 vs. 2.6±1.1%, p<0.0001). However, there was no relationship between FOS dose (mg/day) and EPA+DHA levels in 76 patients reporting FOS use (r=−0.21, p=0.07). Lower levels were inversely associated with risk factor profiles including lower ApoB100/ApoA1 ratios (p<0.001). Discussion and conclusions Higher EPA+DHA levels characterized patients with lower CAD risk. The lack of relations between FOS dose and plasma EPA+DHA levels likely reflects uncaptured variability in EPA+DHA content of supplements.

KW - Cardiovascular risk

KW - Coronary artery disease

KW - Docosahexaenoic acid

KW - Eicosapentaenoic acid

KW - Fish oil supplements

KW - Omega-3 fatty acids

UR - http://www.scopus.com/inward/record.url?scp=84984670531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984670531&partnerID=8YFLogxK

U2 - 10.1016/j.plefa.2016.08.009

DO - 10.1016/j.plefa.2016.08.009

M3 - Article

C2 - 27720039

AN - SCOPUS:84984670531

VL - 113

SP - 40

EP - 45

JO - Prostaglandins Leukotrienes and Essential Fatty Acids

JF - Prostaglandins Leukotrienes and Essential Fatty Acids

SN - 0952-3278

ER -